Traduction de «non-procedural protective measure for witnesses » (Anglais → Français) :

Protection measures are all measures “aimed at protecting witnesses and collaborators of justice from intimidation and retaliation,” while protection programs refer to “a set of individual protection measures which are described in an agreement between the authorities and the protected witness or collaborator of justice”.

I. deeply concerned by the inadequacy of efforts to conduct thorough investigations into such crimes , the absence of protection measures for witnesses, victims and victims’ families, the lack of information regarding cases and the lack of appropriate medical care for victims,

I. deeply concerned by the inadequacy of efforts to conduct thorough investigations into such crimes, the absence of protection measures for witnesses, victims and victims" families, the lack of information regarding cases and the lack of appropriate medical care for victims,

I. deeply concerned by the inadequacy of efforts to conduct thorough investigations into such crimes, the absence of protection measures for witnesses, victims and victims" families, the lack of information regarding cases and the lack of appropriate medical care for victims,

Therefore, although some progress has been made and some measures have been taken, these are not enough; we need to go much further and, above all, we need to create effective protection measures for witnesses and victims, so that the perpetrators may be punished and the European Parliament’s missions to those countries can always place that item on their agenda.

(Return tabled) Question No. 456 Ms. Kirsty Duncan: With respect to the current pandemic of new influenza A (H1N1): (a) what specific healthcare professional stakeholder groups have been consulted since the beginning of the H1N1 pandemic, what was the consultation process, and what concerns were raised; (b) what concerns from the consultation process have been addressed, what concerns are remaining, and by what date will they be addressed; (c) what, if any, additional funding was requested to address identified challenges; (d) do identified stakeholder groups report there are sufficient human resources and supplies to meet the need du ...[+++]ring a second wave of H1N1 and, if not, what are the identified gaps; (e) what, if any, additional education and training was requested by stakeholder groups; (f) what procedures are in place to ensure applicability, consistency and clarity of protocols to healthcare professional organizations, and do stakeholders report that they are receiving clear, concise, timely messaging; (g) what, if any, differences exist in how healthcare professionals will be protected among provinces and territories; (h) what specific agreements have been made in respect to assuring sufficient human resources during a second wave; (i) what, if any, differences exist between the national guidelines and those of the provinces and territories, with respect to antivirals, N-95 masks, vaccines, and other personal protective measures, and how should healthcare professionals address any discrepancies; (j) what are the known and suspected benefits and risks of the H1N1 vaccine; (k) what non-clinical and clinical trials have been or are being undertaken regarding the H1N1 vaccine, on what dates were they completed, and what are the outcomes of these trials; (l) what possible side effects, including rare events, might be expected with the H1N1 vaccine; (m) what are the possible legal risks associated with an H1N1 vaccination programme, and what efforts have ...